20-44622851-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_000022.4(ADA):c.758G>A(p.Arg253Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000904 in 1,614,228 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000022.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ADA | NM_000022.4 | c.758G>A | p.Arg253Gln | missense_variant | 8/12 | ENST00000372874.9 | NP_000013.2 | |
ADA | NM_001322051.2 | c.686G>A | p.Arg229Gln | missense_variant | 7/11 | NP_001308980.1 | ||
ADA | NM_001322050.2 | c.353G>A | p.Arg118Gln | missense_variant | 7/11 | NP_001308979.1 | ||
ADA | NR_136160.2 | n.850G>A | non_coding_transcript_exon_variant | 8/11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADA | ENST00000372874.9 | c.758G>A | p.Arg253Gln | missense_variant | 8/12 | 1 | NM_000022.4 | ENSP00000361965.4 | ||
ADA | ENST00000695995.1 | c.368G>A | p.Arg123Gln | missense_variant | 5/9 | ENSP00000512318.1 | ||||
ADA | ENST00000695991.1 | c.296G>A | p.Arg99Gln | missense_variant | 4/8 | ENSP00000512314.1 | ||||
ADA | ENST00000696038.1 | n.*580G>A | non_coding_transcript_exon_variant | 7/9 | ENSP00000512344.1 | |||||
ADA | ENST00000696038.1 | n.*580G>A | 3_prime_UTR_variant | 7/9 | ENSP00000512344.1 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152218Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000123 AC: 31AN: 251496Hom.: 0 AF XY: 0.0000883 AC XY: 12AN XY: 135922
GnomAD4 exome AF: 0.0000821 AC: 120AN: 1461892Hom.: 0 Cov.: 33 AF XY: 0.0000811 AC XY: 59AN XY: 727248
GnomAD4 genome AF: 0.000171 AC: 26AN: 152336Hom.: 0 Cov.: 33 AF XY: 0.000201 AC XY: 15AN XY: 74496
ClinVar
Submissions by phenotype
Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 07, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 09, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 253 of the ADA protein (p.Arg253Gln). This variant is present in population databases (rs148994526, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with ADA-related conditions. ClinVar contains an entry for this variant (Variation ID: 536185). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ADA protein function. This variant disrupts the p.Arg253 amino acid residue in ADA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8258146, 9758612). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 28, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jun 10, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at